Regeneron vs Zoetis (REGN vs ZTS)

Regeneron (REGN) vs Zoetis (ZTS) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

Regeneron (REGN) and Zoetis (ZTS) compete in healthcare and pharma. Here are Regeneron and Zoetis side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Regeneron or Zoetis.

Regeneron vs Zoetis: the figures

Regeneron and Zoetis figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Regeneron or Zoetis figure is not available, and we never estimate it.

3 key differences between Regeneron and Zoetis

1. Growth: Regeneron grew sales +36.3% year on year in its latest quarter, against -0.2% for Zoetis.
2. Debt: Zoetis owes 1.9x its annual operating profit (EBITDA), while Regeneron holds more cash than debt.
3. Dividend: Zoetis yields 2.55% at today's price and Regeneron yields 0.39%.

Regeneron or Zoetis: which fits your profile

• If you want growth: Regeneron is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): Zoetis pays the higher dividend relative to its price.
• If you prefer caution: Regeneron has less debt relative to its profit, which usually gives more room in a bad year.
• If price is what matters most to you: Zoetis trades on the lower P/E; check first whether that is an opportunity or a sign of a business that grows less.

Neither Regeneron nor Zoetis wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How Regeneron and Zoetis make money

Regeneron (REGN)

Regeneron is a biotech company built on antibody drugs. It earns money from U.S. sales of Eylea for retinal eye disease and from its partnership with Sanofi on Dupixent, used for eczema and asthma, which the two companies share profits on. It also sells the cancer immunotherapy Libtayo. Full Regeneron analysis.

Zoetis (ZTS)

Zoetis makes medicines, vaccines and diagnostics for animals. Companion animal products such as Simparica, Apoquel and Librela for dogs and cats bring in most of its sales, while livestock products treat cattle, pigs, poultry and fish. The company reports two segments: United States and International. Full Zoetis analysis.

Frequently asked questions: Regeneron vs Zoetis

Is Regeneron or Zoetis the better stock?

Choosing between Regeneron and Zoetis depends on what you are looking for. Regeneron is growing faster right now, and Zoetis trades on the lower P/E. Fintols does not tell you whether to buy Regeneron or Zoetis: it shows you the differences so you can decide.

Which pays a higher dividend, Regeneron or Zoetis?

As of November 4, 2026, Zoetis yields 2.55% and Regeneron yields 0.39%. Also check how much of their profit Regeneron and Zoetis pay out: if it is more than they earn, it cannot last.

Which is more expensive, Regeneron or Zoetis?

On P/E, Regeneron (20.6x) is more expensive than Zoetis (14.7x) as of November 4, 2026. A higher P/E can be justified if earnings grow faster, so compare it with each company's growth in the table.

Can I own both Regeneron and Zoetis?

Yes. Many people spread their money across several companies, such as Regeneron and Zoetis, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Regeneron or Zoetis.

More comparisons with Regeneron or Zoetis

• Cigna vs Regeneron
• Elevance Health vs Regeneron
• Cigna vs Zoetis
• Elevance Health vs Zoetis

More companies like Regeneron and Zoetis: healthcare and pharma stocks. Educational content about Regeneron and Zoetis, not investment advice.